Figure 1.

The cumulative incidence function from the ASCOT-LLA trial for the primary endpoint of non-fatal MI and fatal coronary heart disease.^[62] Treatment with atorvastatin was associated with a 36% reduction in the risk of the primary endpoint with a median follow-up of 3.3 years. One could speculate, but could not be certain, whether TTB was earlier than 3.3 years, unless it was reported in the trial. One also cannot quantify the ARR at an earlier time point with certainty. Reprinted from The Lancet, Vol. 361 number 9364, Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial, Pages 1149–1158, Copyright (2003), with permission from Elsevier.

The survival curve from the PREVEND-IT trial for cardiovascular events in subjects with microalbuminuria.^[35] In this case, treatment with pravastatin did not prevent cardiovascular events, and this can be clearly seen on the survival curve, showing no sustained separation between treatment and placebo. Reprinted with permission from Wolters Kluwer Health from Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809-16.